- Home
- GIB vs BIIB Comparison
GIB vs BIIB Comparison
Compare GIB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIB
- BIIB
- Stock Information
- Founded
- GIB 1976
- BIIB 1978
- Country
- GIB Canada
- BIIB United States
- Employees
- GIB N/A
- BIIB N/A
- Industry
- GIB Professional Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GIB Consumer Discretionary
- BIIB Health Care
- Exchange
- GIB Nasdaq
- BIIB Nasdaq
- Market Cap
- GIB 23.1B
- BIIB 19.9B
- IPO Year
- GIB N/A
- BIIB 1991
- Fundamental
- Price
- GIB $100.79
- BIIB $132.03
- Analyst Decision
- GIB Buy
- BIIB Buy
- Analyst Count
- GIB 4
- BIIB 27
- Target Price
- GIB $156.75
- BIIB $220.50
- AVG Volume (30 Days)
- GIB 297.0K
- BIIB 1.7M
- Earning Date
- GIB 04-30-2025
- BIIB 04-23-2025
- Dividend Yield
- GIB 0.22%
- BIIB N/A
- EPS Growth
- GIB 9.08
- BIIB 40.28
- EPS
- GIB 5.26
- BIIB 11.18
- Revenue
- GIB $10,326,670,790.00
- BIIB $9,675,900,000.00
- Revenue This Year
- GIB $10.63
- BIIB N/A
- Revenue Next Year
- GIB $5.00
- BIIB N/A
- P/E Ratio
- GIB $19.19
- BIIB $11.81
- Revenue Growth
- GIB 2.83
- BIIB N/A
- 52 Week Low
- GIB $96.75
- BIIB $128.51
- 52 Week High
- GIB $122.79
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- GIB 41.17
- BIIB 33.63
- Support Level
- GIB $96.75
- BIIB $138.65
- Resistance Level
- GIB $101.67
- BIIB $144.07
- Average True Range (ATR)
- GIB 2.19
- BIIB 3.56
- MACD
- GIB 0.26
- BIIB -0.86
- Stochastic Oscillator
- GIB 51.53
- BIIB 2.79
About GIB CGI Inc.
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company generates more than CAD 14 billion in annual revenue, employs over 90,000 personnel, and operates across 400 offices in 40 countries. CGI offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services. Its largest vertical market is government, which contributes more than a third of group revenue.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.